# Etirinotecan Pegol (NKTR-102) in NSCLC

> **NCT01773109** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 40 (actual)

## Conditions studied

- Metastatic Non Small Cell Lung Cancer
- Recurrent Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Etirinotecan pegol (NKTR-102)

## Key facts

- **NCT ID:** NCT01773109
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2016-01
- **Final completion:** 2017-03-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01773109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01773109, "Etirinotecan Pegol (NKTR-102) in NSCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01773109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*